|
 |
|
Volume 2, Number 2, Supplement 2 (March/April 2004) | ||||
| Annual Review of Cytokines in Cancer Management | ||||
|
Summaries of selected papers presented at eight major oncology meetings: 2003 Annual Meeting of the American College of Clinical Pharmacy • 39th Annual Meeting of the American Society of Clinical Oncology • 45th Annual Meeting of the American Society of Hematology • 38th Midyear Clinical Meeting of the American Society of Health-System Pharmacists • 28th Annual Congress of the Oncology Nursing Society • 26th Annual San Antonio Breast Cancer Symposium • Eighth International Conference on Geriatric Oncology: Cancer in the Elderly • 10th World Conference on Lung Cancer |
||||
Anemia |
||||
2 |
The Emerging Role of Darbepoetin Alfa in the Management of Patients With Cancer University of Arizona Health Sciences Center and Department of Medicine, Section of Hematology/Oncology, University of Arizona College of Medicine, Phoenix, Arizona
|
|||
4 |
The Impact of Medical Visits on Patients With Cancer
| |||
6 |
Usage and Clinical Outcomes of Erythropoietic Proteins for the Treatment of Chemotherapy-Induced Anemia: Clinical Evaluation of Anemia Response (CLEAR), a Multicenter, Retrospective Cohort Study
| |||
8 |
Dosing Patterns and Clinical Outcomes of Erythropoietic Agents for the Treatment of Anemia in Patients With Nonmyeloid Malignancies Receiving Chemotherapy
| |||
10 |
Darbepoetin Alfa Is Comparable to Epoetin Alfa for Chemotherapy-Induced Anemia in Clinical Practice
| |||
12 |
Institutional Guidelines for Therapeutic Substitution With Darbepoetin Alfa: Hematologic Outcomes in Patients With Chemotherapy-Induced Anemia
| |||
14 |
Darbepoetin Alfa Administered Every Two Weeks Reduces Chemotherapy-Induced Anemia to the Same Extent as Recombinant Human Erythropoietin (Epoetin Alfa), But With Less-Frequent Dosing
| |||
16 |
Early Results of a Head-To-Head Comparison of Darbepoetin Alfa 200 µg Given Every 2 Weeks and Epoetin Alfa 40,000 U Given Weekly
| |||
18 |
Darbepoetin Alfa 3.0 µg/kg Every 2 Weeks Improves Hemoglobin and Quality of Life in a Subset of Breast Cancer Patients in a Community-Based Trial of Patients With Chemotherapy-Induced Anemia
| |||
20 |
Front-Loaded Darbepoetin Alfa Administered as a Fixed or Weight-Based Dose With Every-3-Week Maintenance Has Similar Efficacy in Anemic Cancer Patients
| |||
22 |
Effects of Darbepoetin Alfa Timing With Chemotherapy Administration: A Randomized Study
| |||
24 |
A Randomized Study of Darbepoetin Alfa Every 3 Weeks for Chemotherapy-Induced Anemia
| |||
26 |
Every-2-Week Dosing of Darbepoetin Alfa in Patients With Anemia of Cancer: Interim Analysis of a Randomized, Controlled Study
| |||
28 |
Darbepoetin Alfa Is an Effective Therapy for Anemia Following Allogeneic Stem-Cell Transplantation
| |||
30 |
A Dose-Finding and Safety Study of Darbepoetin Alfa for the Treatment of Anemia in Patients With Thalassemia Intermedia
| |||
32 |
An Open-Label, Randomized Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa
| |||
34 |
Assessing Symptom Burden Using the M. D. Anderson Symptom Inventory (MDASI) in Patients With Chemotherapy-Induced Anemia: Early Results of a Multicenter, Open-Label Study of Patients Treated With Darbepoetin Alfa 200 µg Every 2 Weeks
| |||
Neutropenia |
||||
36 |
Improving the Management of Chemotherapy-Induced Neutropenia Department of Medicine, Division of Medical Oncology, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina
| |||
40 |
Time to First Neutropenia Hospitalization During First-Course Chemotherapy Among Newly Diagnosed Non-Hodgkin’s Lymphoma Patients: National SEER-Medicare Study
| |||
42 |
The Role of Granulopoiesis-Stimulating Factors in the Treatment
of Malignant Lymphoma: Recent Update of a Comprehensive
Meta-Analysis
| |||
44 |
Effects of G-CSF Schedule on Leukocyte Recovery and Infection Rate in the CHOP-14 Regimen for Elderly Patients With Aggressive Lymphoma
| |||
46 |
Single Administration of Fixed-Dose Pegfilgrastim in Inducing Neutrophil Count Recovery After 170 Consecutive Doses of ABVD Chemotherapy in Patients With Hodgkin’s Lymphoma: Safety of Pegfilgrastim With Every-14-Day Chemotherapy Regimens
| |||
48 |
Pegfilgrastim Serum Concentrations on the Twelfth Day After Dosing Are Unlikely to Stimulate Granulopoiesis: A Retrospective Analysis of Six Clinical Trials in a Variety of Cancer Populations
| |||
50 |
Most Patients Treated With Adjuvant Chemotherapy for Breast Cancer Receive Substantially Reduced Dose Intensity
| |||
52 |
A Pretreatment Risk Model to Predict Dose Attenuation of Adjuvant Chemotherapy in Patients With Early-Stage Breast Cancer
| |||
54 |
Community Experience With Filgrastim in Diverse Nonmyeloid Malignancies: An Open-Label Phase IV Study
| |||
56 |
Utilization of Granulocyte Colony-Stimulating Factor in Non-Small Cell Lung Cancer Patients Receiving Carboplatin-Based Chemotherapy
| |||
58 |
Pegfilgrastim Supports Dose-Dense Carboplatin/Vinorelbine in the Treatment of Thoracic Malignancies
| |||
60 |
Potential Cost Savings When Switching From Filgrastim to Pegfilgrastim
| |||
62 |
Economic Impact of Pegfilgrastim Use Based on the Risk of Febrile Neutropenia in Non-Hodgkin’s Lymphoma Patients Treated With CHOP
| |||
64 |
The Impact of Chemotherapy Delays on Quality of Life in
Patients With Cancer
| |||
66 |
The Experience of Chemotherapy-Induced Neutropenia:
Quality-of-Life Interviews With Adult Cancer Patients
| |||
68 |
Analysis of Dendritic Cell Content Within Allografts Mobilized Following G-CSF or GM-CSF Does Not Reveal Significant Differences
in DC1 or DC2 Subsets
| |||
Mucositis |
||||
70 |
The Challenges of Oral Mucositis and Its Therapy Departments of Medicine and Pathology, Cardinal Bernardin Cancer Center, and Division of Hematology-Oncology, Loyola University Medical Center, Maywood, Illinois
| |||
73 |
Use of Recombinant Human Keratinocyte Growth Factor (Palifermin) Can Reduce Severe Oral Mucositis in Patients With Hematologic Malignancies Undergoing Autologous Peripheral Blood Progenitor Cell Transplantation After Radiation-Based Conditioning
| |||
75 |
Treatment of Mucositis With Palifermin Improves Patient Function and Results in a Clinically Meaningful Reduction in Mouth and Throat Soreness: Phase III Results
| |||
77 |
Palifermin Treatment of Mucositis in Transplant Patients Reduces Health Resource Use: Phase III Results
| |||
79 |
Impact of Oral Mucositis and Its Sequelae on Quality of Life
| |||
Supported by an unrestricted educational grant from Amgen Inc. |
||||
© 2004 by BioLink Communictions, Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. |
||||
21 kb